A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome t(9;22)(q34;q11.2), which ultimately forms the BCR-ABL oncoprotein [1]. Tyrosine kinase inhibitors (TKIs) directed against the tyrosine kinase activity of BCR-ABL are the primary therapeutic option in CML and have proven to be extremely effective at inducing hematologic, cytogenetic, and molecular remissions. Five TKIs are currently approved by health authorities for the treatment of CML: the first-generation TKI imatinib; the second-generation TKIs dasatinib, nilotinib, and bosutinib; and the third-generation TKI ponatinib [2 –6].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research